Akiba, Hiroki http://orcid.org/0000-0002-1450-5873
Fujita, Junso http://orcid.org/0000-0003-1273-3917
Ise, Tomoko
Nishiyama, Kentaro http://orcid.org/0000-0002-2238-2463
Miyata, Tomoko http://orcid.org/0000-0002-5543-7459
Kato, Takayuki http://orcid.org/0000-0002-8879-6685
Namba, Keiichi http://orcid.org/0000-0003-2911-5875
Ohno, Hiroaki http://orcid.org/0000-0002-3246-4809
Kamada, Haruhiko http://orcid.org/0000-0002-2478-3818
Nagata, Satoshi http://orcid.org/0000-0001-9156-5215
Tsumoto, Kouhei http://orcid.org/0000-0001-7643-5164
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (JP21K06453, JP20K22630)
Takeda Science Foundation
Kyoto University Foundation
Japan Agency for Medical Research and Development (JP21am0101117, JP22ama121003, JP17pc0101020, JP22ak0101099)
MEXT | Japan Science and Technology Agency (JPMJOP1861)
JEOL YOKOGUSHI Research Alliance Laboratory of Osaka University
Article History
Received: 7 March 2023
Accepted: 6 September 2023
First Online: 27 September 2023
Competing interests
: H.A., S.N., and K.T. filed a patent related to the described biparatopic antibodies (WO2021200840). H.K. and S.N. are co-founders of Epitope Science Co., Ltd. The other authors have no conflicts of interest to declare.